OUTLOOK THERAPEUTICS, INC. (OTLK) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.87M; Additional Paid in Capital, Common StockUSD $641.28M; Retained Earnings (Accumulated Deficit)USD $-653.54M; Stockholders' Equity Attributable to ParentUSD $-10.39M.
- 2026-03-31: Common Stock, Value, IssuedUSD $1.05M; Additional Paid in Capital, Common StockUSD $603.18M; Retained Earnings (Accumulated Deficit)USD $-633.22M; Stockholders' Equity Attributable to ParentUSD $-28.99M.
- 2025-12-31: Common Stock, Value, IssuedUSD $645.57K; Additional Paid in Capital, Common StockUSD $589.57M; Retained Earnings (Accumulated Deficit)USD $-628.77M; Stockholders' Equity Attributable to ParentUSD $-38.55M.
- 2025-09-30: Common Stock, Value, IssuedUSD $538.87K; Additional Paid in Capital, Common StockUSD $572.98M; Retained Earnings (Accumulated Deficit)USD $-605.71M; Stockholders' Equity Attributable to ParentUSD $-32.19M.
OUTLOOK THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | Additional Paid in Capital USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Redeemable USD | Noncontrolling Interest, Decrease from Deconsolidation USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.87M | $641.28M | $-653.54M | $-10.39M | 3 month · $791.67K | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $1.05M | $603.18M | $-633.22M | $-28.99M | 3 month · $757.48K | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $645.57K | $589.57M | $-628.77M | $-38.55M | 3 month · $881.15K | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $538.87K | $572.98M | $-605.71M | $-32.19M | 12 month · $8.90M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $434.79K | $554.79M | $-592.42M | $-37.19M | 3 month · $1.68M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $329.07K | $539.47M | $-572.26M | $-32.46M | 3 month · $1.72M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $249.06K | $475.37M | $-525.91M | $-50.29M | 3 month · $3.67M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $239.06K | $469.97M | $-543.28M | $-73.08M | 12 month · $5.39M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $234.06K | $465.07M | $-548.98M | $-83.67M | 3 month · $1.40M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $220.13K | $458.93M | $-593.39M | $-134.24M | 3 month · $1.31M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $2.60M | $452.15M | $-479.10M | $-24.34M | 3 month · $1.27M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $130.13K | $453.35M | $-467.92M | $-14.44M | 12 month · $5.55M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $2.59M | $446.84M | $-454.93M | $-5.50M | 3 month · $1.38M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $2.57M | $442.17M | $-434.25M | $10.49M | 3 month · $1.38M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $2.57M | $440.79M | $-427.60M | $15.76M | 3 month · $1.39M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $2.27M | $415.40M | $-408.94M | $8.74M | 12 month · $7.71M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $2.26M | $412.41M | $-394.59M | $20.08M | 3 month · $1.37M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $2.26M | $410.76M | $-377.05M | $35.96M | 3 month · $3.76M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $2.24M | $403.93M | $-357.35M | $48.82M | 3 month · $1.20M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $1.76M | $345.73M | $-342.88M | $4.61M | 12 month · $4.89M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $1.75M | $340.48M | $-329.48M | $12.75M | 3 month · $1.20M 9 month · $3.48M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $1.74M | $336.20M | $-317.28M | $20.65M | 3 month · $1.13M 6 month · $2.28M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $1.27M | $292.43M | $-304.18M | $-10.47M | 3 month · $1.15M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $1.27M | $291.27M | $-289.72M | $2.83M | 12 month · $2.81M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $1.26M | $289.50M | $-279.80M | $10.97M | 3 month · $1.36M 9 month · $2.02M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $897.51K | $255.36M | $-276.78M | $-20.52M | 3 month · $304.54K 6 month · $664.02K | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $384.31K | $239.77M | $-271.08M | $-30.93M | 3 month · $359.48K | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $286.10K | $238.06M | $-254.48M | $-16.13M | 12 month · $1.31M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $282.33K | $237.55M | $-244.38M | $-6.56M | 3 month · $-31.27K 9 month · $1.11M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $117.60K | $211.74M | $-239.94M | $-28.09M | 3 month · $267.74K 6 month · $1.14M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $850.92K | $202.49M | $-229.70M | $-26.35M | 3 month · $872.29K | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $90.28K | $190.67M | $-216.31M | $-25.54M | 12 month · $1.99M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $721.99K | $190.19M | $-204.11M | $-13.20M | 3 month · $234.12K 9 month · $1.82M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $257.40K | $159.19M | $-195.68M | $-33.57M | 3 month · $-300.21K 6 month · $1.59M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $255.31K | $160.13M | $-188.14M | $-25.09M | 3 month · $1.89M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $249.34K | $152.32M | $-186.22M | $-33.65M | 12 month · $8.57M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $246.59K | (m) | $-179.86M | $-28.94M | 9 month · $6.91M | (m) | $150.68M | (m) | (m) | (m) |
| 2017-03-31 | $241.00K | (m) | $-174.54M | $-26.85M | 6 month · $4.79M | (m) | $147.44M | (m) | (m) | (m) |
| 2016-12-31 | $235.88K | (m) | $-166.49M | $-21.83M | 3 month · $2.46M | (m) | $144.42M | (m) | (m) | (m) |
| 2016-09-30 | $228.03K | $141.97M | $-147.37M | $-5.17M | 12 month · $10.06M | (m) | $141.97M | $-5.20M | (m) | 12 month · $654.42K |
| 2016-06-30 | (m) | (m) | $-136.80M | $1.56M | 9 month · $6.23M | (m) | $138.13M | $1.56M | (m) | 9 month · $654.42K |
| 2016-03-31 | (m) | (m) | $-114.47M | $-37.86M | 6 month · $-4.35M | $118.00 | $76.48M | $-37.86M | (m) | 6 month · $654.42K |
| 2015-09-30 | $39.84M | (m) | $-94.06M | $-54.22M | 12 month · $8.93K | (m) | (m) | $-54.87M | 12 month · $401.00K | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |